Table 1. Amyloid-β lysine K28 accessibility for covalent modification with CPP in AD and LBD patient prefrontal cortex samples.
The table shows the accessibility in percent for Ab#K28 and SDHB#K137, and TUBB#K174 lysine sites in 10 patient and 10 control samples in total lysate or the precipitate following ultracentrifugation of the lysate. Abbreviations: SpC, spectrum count; %acc, percentile of peptide in which the lysine site was accessible for covalent modification.
| Ab#K28 | SDHB#K137 | TUBB#K174 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Lysate | Pellet | Lysate | Lysate | ||||||
| Diagnosis | Sample | SpC | %acc | SpC | %acc | SpC | %acc | SpC | %acc |
| AD | A10 | 2 | 89 | 2 | 99 | 0 | n.d. | 2 | 98 |
| AD | A7 | 4 | 79 | 7 | 92 | 2 | 58 | 1 | 99 |
| AD | A4 | 7 | 65 | 5 | 92 | 4 | 56 | 1 | 99 |
| AD-dLBD | A6 | 4 | 75 | 5 | 94 | 2 | 58 | 2 | 98 |
| AD-dLBD | BIO | 7 | 84 | 6 | 94 | 2 | 62 | 2 | 98 |
| AD-dLBD | B6 | 6 | 51 | 7 | 86 | 2 | 61 | 1 | 98 |
| AD-dLBD | A9 | 6 | 49 | 5 | 82 | 1 | 72 | 1 | 99 |
| AD-dLBD | B7 | 7 | 48 | 8 | 51 | 2 | 60 | 2 | 99 |
| AD-dLBD | B8 | 6 | 62 | 5 | 84 | 1 | 56 | 2 | 97 |
| LBD | B5 | 0 | n.d. | 0 | n.d. | 2 | 57 | 2 | 98 |
| Normal | A1 | 0 | n.d. | 0 | n.d. | 0 | n.d. | 2 | 99 |
| Normal | A2 | 0 | n.d. | 0 | n.d. | 0 | n.d. | 1 | 98 |
| Normal | A3 | 0 | n.d. | 0 | n.d. | 2 | 91 | 1 | 99 |
| Normal | A5 | 0 | n.d. | 0 | n.d. | 0 | n.d. | 2 | 99 |
| Normal | A8 | 0 | n.d. | 0 | n.d. | 0 | n.d. | 1 | 99 |
| Normal | B1 | 0 | n.d. | 0 | n.d. | 1 | 80 | 1 | 99 |
| Normal | B3 | 0 | n.d. | 0 | n.d. | 2 | 80 | 2 | 99 |
| Normal | B9 | 0 | n.d. | 0 | n.d. | 0 | n.d. | 1 | 99 |
| Normal | B4 | 0 | n.d. | 0 | n.d. | 2 | 79 | 2 | 99 |
| Normal | B2 | 3 | 7 | 1 | 4 | 2 | 78 | 2 | 99 |